BIOXCEL THERAPEUTICS INC (BTAI) Stock Fundamental Analysis
NASDAQ:BTAI - Nasdaq - US09075P2048 - Common Stock - Currency: USD
We assign a fundamental rating of 1 out of 10 to BTAI. BTAI was compared to 555 industry peers in the Biotechnology industry. BTAI has a bad profitability rating. Also its financial health evaluation is rather negative. BTAI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BTAI had negative earnings in the past year.
BTAI had a negative operating cash flow in the past year.
BTAI had negative earnings in each of the past 5 years.
In the past 5 years BTAI always reported negative operating cash flow.
1.2 Ratios
BTAI has a Return On Assets of -103.88%. This is in the lower half of the industry: BTAI underperforms 77.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -103.88% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-159.63%
ROA(5y)-112.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BTAI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BTAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BTAI has been increased compared to 1 year ago.
The number of shares outstanding for BTAI has been increased compared to 5 years ago.
BTAI has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -27.72, we must say that BTAI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -27.72, BTAI is doing worse than 89.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -27.72 |
ROIC/WACCN/A
WACC7.13%
2.3 Liquidity
A Current Ratio of 1.48 indicates that BTAI should not have too much problems paying its short term obligations.
With a Current ratio value of 1.48, BTAI is not doing good in the industry: 81.62% of the companies in the same industry are doing better.
BTAI has a Quick Ratio of 1.45. This is a normal value and indicates that BTAI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.45, BTAI is doing worse than 81.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.48 | ||
| Quick Ratio | 1.45 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 83.65% over the past year.
Looking at the last year, BTAI shows a small growth in Revenue. The Revenue has grown by 5.35% in the last year.
EPS 1Y (TTM)83.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.22%
Revenue 1Y (TTM)5.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-71.13%
3.2 Future
Based on estimates for the next years, BTAI will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.22% on average per year.
BTAI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 151.92% yearly.
EPS Next Y66.91%
EPS Next 2Y31.34%
EPS Next 3Y26.51%
EPS Next 5Y15.22%
Revenue Next Year-15.93%
Revenue Next 2Y81.31%
Revenue Next 3Y245.37%
Revenue Next 5Y151.92%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BTAI. In the last year negative earnings were reported.
Also next year BTAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BTAI's earnings are expected to grow with 26.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.34%
EPS Next 3Y26.51%
5. Dividend
5.1 Amount
BTAI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.93
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners11.02%
Inst Owner Change-94.6%
Ins Owners0.76%
Ins Owner Change11.94%
Market Cap11.70M
Analysts74.55
Price Target17.75 (819.69%)
Short Float %5.74%
Short Ratio1.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.72%
Min EPS beat(2)45.53%
Max EPS beat(2)77.91%
EPS beat(4)4
Avg EPS beat(4)59.13%
Min EPS beat(4)42.08%
Max EPS beat(4)77.91%
EPS beat(8)5
Avg EPS beat(8)25.09%
EPS beat(12)5
Avg EPS beat(12)11.68%
EPS beat(16)8
Avg EPS beat(16)10.75%
Revenue beat(2)0
Avg Revenue beat(2)-55.31%
Min Revenue beat(2)-61.4%
Max Revenue beat(2)-49.22%
Revenue beat(4)1
Avg Revenue beat(4)-38%
Min Revenue beat(4)-83.93%
Max Revenue beat(4)42.56%
Revenue beat(8)2
Avg Revenue beat(8)-28.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-36.73%
PT rev (3m)-37.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.44%
EPS NY rev (1m)51.37%
EPS NY rev (3m)50.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-47.83%
Revenue NY rev (1m)-17.45%
Revenue NY rev (3m)-42.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.32 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-13.55
EYN/A
EPS(NY)-7.14
Fwd EYN/A
FCF(TTM)-10.95
FCFYN/A
OCF(TTM)-10.95
OCFYN/A
SpS0.31
BVpS-14.88
TBVpS-14.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -103.88% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-159.63%
ROA(5y)-112.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.48 | ||
| Quick Ratio | 1.45 | ||
| Altman-Z | -27.72 |
F-Score2
WACC7.13%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.22%
EPS Next Y66.91%
EPS Next 2Y31.34%
EPS Next 3Y26.51%
EPS Next 5Y15.22%
Revenue 1Y (TTM)5.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-71.13%
Revenue Next Year-15.93%
Revenue Next 2Y81.31%
Revenue Next 3Y245.37%
Revenue Next 5Y151.92%
EBIT growth 1Y63.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.06%
EBIT Next 3Y29.12%
EBIT Next 5Y20.3%
FCF growth 1Y57.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.26%
OCF growth 3YN/A
OCF growth 5YN/A